These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9616275)

  • 1. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.
    Castiglione-Gertsch M; Tattersall M; Hacking A; Goldhirsch A; Gudgeon A; Gelber RD; Lindtner J; Coates A; Collins J; Isley M; Senn HJ; Rudenstam CM
    Eur J Cancer; 1997 Dec; 33(14):2321-5. PubMed ID: 9616275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
    Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group.
    Wallgren A; Bernier J; Gelber RD; Goldhirsch A; Roncadin M; Joseph D; Castiglione-Gertsch M
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):649-59. PubMed ID: 8690630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).
    Goldhirsch A; Colleoni M; Coates AS; Castiglione-Gertsch M; Gelber RD
    Ann Oncol; 1998 May; 9(5):489-93. PubMed ID: 9653488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.
    Marini G; Murray S; Goldhirsch A; Gelber RD; Castiglione-Gertsch M; Price KN; Tattersall MH; Rudenstam CM; Collins J; Lindtner J; Cavalli F; Cortés-Funes H; Gudgeon A; Forbes JF; Galligioni E; Coates AS; Senn HJ
    Ann Oncol; 1996 Mar; 7(3):245-50. PubMed ID: 8740787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
    Goldhirsch A; Gelber RD; Price KN; Castiglione M; Coates AS; Rudenstam CM; Collins J; Lindtner J; Hacking A; Marini G
    Lancet; 1994 Feb; 343(8894):377-81. PubMed ID: 7905550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
    Valagussa P; Tancini G; Bonadonna G
    Cancer; 1986 Oct; 58(7):1411-7. PubMed ID: 3755647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
    International Breast Cancer Study Group
    J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
    Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
    Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
    Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
    Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.
    Goldhirsch A; Coates AS; Colleoni M; Castiglione-Gertsch M; Gelber RD
    J Clin Oncol; 1998 Apr; 16(4):1358-62. PubMed ID: 9552037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brunelli A; Brizzi MP; Di Marco B; Cirillo F; Tampellini M; Bolsi G; Aguggini S; Betri E; Filippini L; Bertoli A; Alquati P; Dogliotti L
    Int J Oncol; 1998 Aug; 13(2):385-90. PubMed ID: 9664137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.